Application Segment Analysis: Susceptibility Testing (Largest Segment) vs Drug Development (Fastest-Growing Segment)

In the antimicrobial susceptibility testing market, susceptibility testing held the largest share in 2026, reflecting its fundamental role in guiding appropriate antimicrobial treatment decisions. These tests enable healthcare professionals to determine how effectively specific microorganisms respond to available antimicrobial agents, supporting more informed therapy selection and helping address the growing challenge of antimicrobial resistance. Their importance extends across clinical microbiology laboratories, hospitals, and diagnostic settings where timely identification of effective treatment options is essential. Increasing attention to antimicrobial stewardship and the need to reduce inappropriate antibiotic use continue to reinforce demand for susceptibility testing.

Drug development is the fastest-growing application segment, supported by the increasing need to evaluate antimicrobial candidates against resistant pathogens during research and development activities. Susceptibility testing provides critical evidence on the effectiveness of emerging compounds and helps researchers characterize pathogen responses during the development process. Rising scientific focus on novel antimicrobial therapies, particularly those capable of addressing resistant infections, is increasing the importance of testing platforms within pharmaceutical and research workflows. Advances in laboratory methods and growing investment in antimicrobial discovery are consequently creating stronger opportunities for this application.

Product Segment Analysis: Manual Tests (Largest Segment) vs Automated Instruments (Fastest-Growing Segment)

Manual tests accounted for the largest share of the antimicrobial susceptibility testing market in 2026, supported by their broad applicability, established laboratory workflows, and accessibility across diverse testing environments. Conventional methods remain important because they can be implemented without highly complex infrastructure and provide laboratories with practical approaches for assessing antimicrobial response. Their continued use is particularly relevant in settings where cost considerations, established operating procedures, and flexibility in test selection influence purchasing decisions. The longstanding familiarity of laboratory personnel with manual susceptibility testing also contributes to its continued market presence.

Automated instruments are experiencing the fastest growth as laboratories increasingly prioritize rapid, standardized, and efficient antimicrobial susceptibility testing. Automated systems can streamline specimen processing, reduce manual intervention, and support consistent interpretation of test results, making them valuable for laboratories managing substantial testing workloads. Their integration with laboratory information systems and broader diagnostic automation also improves workflow coordination and supports faster clinical decision-making. As healthcare facilities place greater emphasis on operational efficiency, antimicrobial stewardship, and timely detection of resistant organisms, automated instruments are gaining increasing relevance.